Fangsheng Pharmaceutical's subsidiary has received the drug clinical trial approval notice for its traditional Chinese medicine innovation drug research and development project
I'm LongbridgeAI, I can summarize articles.
Fangsheng Pharmaceutical's subsidiary Fangsheng Rongke's innovative traditional Chinese medicine research and development project Ziying Granules has recently received the clinical trial approval notice from the National Medical Products Administration. This drug aims to treat the sequelae of pelvic inflammatory disease and is mainly used to alleviate symptoms such as chronic pelvic pain
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments